Matthew Solhjem, MD
Radiation Oncology · Portland, ORNPI 1356334403
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,501 of the $2,150 with a category attached, or 69.8%. 9 manufacturers reported payments, led by Teleflex LLC at 51.6% of the total. Reporting peaked in 2024 at $1,024 and has fallen 64.1% since, to $368 in 2025.
Across 22 payments — averaging $97.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$1K
- Siemens Medical Solutions USA, Inc.$331
- Elekta, Inc.$284
- Sumitomo Pharma America, Inc.$176
- Progenics Pharmaceuticals, Inc.$125
- Viewray Technologies Inc$36
- plus $88 from 3 others
What the payments were for
- Travel & lodging$64930%
- Food & beverage$1,50170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 6 | $1,110 |
| Siemens Medical Solutions USA, Inc. | 3 | $331 |
| Elekta, Inc. | 3 | $284 |
| Sumitomo Pharma America, Inc. | 3 | $176 |
| Progenics Pharmaceuticals, Inc. | 1 | $125 |
| Viewray Technologies Inc | 2 | $36 |
| Telix Pharmaceuticals | 1 | $33 |
| Boston Scientific | 2 | $29 |
| Myovant Sciences Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,150 in reported general payments places this provider in the 85th percentile of 93 radiation oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 151 | $1,704 |
| Pentoxifylline | 15 | $642 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 27 | $235 |
| Oxybutynin Chloride ErOxybutynin Chloride | 19 | $158 |
| Methylprednisolone | 11 | $87 |
| Oxycodone Hcl | 11 | $57 |
| Lorazepam | 12 | $29 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Portland
- Marka CrittendenPortland$20K
- Steven SeungPortland$11K
- Joshua WalkerPortland$9K
- Andrew KeePortland$7K
- Brandon DyerPortland$4K
- Nima NabavizadehPortland$4K
- Amar SrivastavaPortland$4K
- Re-I ChinPortland$3K
- Akanksha RajeursPortland$2K
- Kristina YoungPortland$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.